Enoximone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Enoximone
Enoximone.svg
Clinical data
Trade namesPerfan
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability50% (oral)
Protein binding85%
MetabolismLiver (oxidation)
Elimination half-life4 to 10 hours
ExcretionRenal (60 to 70%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H12N2O2S
Molar mass248.302 g/mol g·mol−1
3D model (JSmol)
Melting point255 to 258 °C (491 to 496 °F) (decomposes)
  (verify)

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.[1]

Synthesis[edit]

[2]

Prepn: BE 883856  (1980 to Richardson-Merrell); R. A. Schnettler et al., U.S. Patent 4,405,635 (1983 to Merrell-Dow)

References[edit]

  1. ^ Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother. 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID 17714066.
  2. ^ Schnettler, Richard A.; Dage, Richard C.; Grisar, J. Martin (1982). "4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents". Journal of Medicinal Chemistry. 25 (12): 1477–1481. doi:10.1021/jm00354a017. ISSN 0022-2623.